Seed, the #1 Gut Health Supplements Brand in the U.S., Launches Nationwide at Costco
Seed, the #1 Gut Health Supplements Brand in the U.S., Launches Nationwide at Costco
PR Newswire
NEW YORK, Nov. 9, 2026
The microbiome science company brings its flagship DS-01® Daily Synbiotic to all Costco locations in a Costco-exclusive 100-count format, marking its first entry into the club channel
NEW YORK, Nov. 9, 2026 /PRNewswire/ -- Seed, a microbiome science company, today announced its nationwide launch at Costco, marking the company's first entry into the club channel. Beginning today, Costco members can shop Seed's award-winning DS-01® Daily Synbiotic in a Costco-exclusive 100-count jar, a 50-day supply ($74.99).
The launch marks the latest milestone in Seed's growth as the number-one gut health supplements brand in the U.S. Over the past five years, Seed has grown revenue 13x while remaining profitable, establishing a strong omnichannel presence across Amazon, Target, Sprouts Farmers Market, and Erewhon. That expansion has been met with strong consumer demand, with DS-01® becoming the leading digestive health probiotic at both Target and Amazon. Costco now brings Seed into its largest retail channel yet, significantly expanding the brand's reach.
"We've been deliberate about building a business that can scale while maintaining the scientific rigor, product efficacy, and experience that define Seed," said Cathrin Bowtell, CEO of Seed Health. "Costco represents an important next step in that strategy, allowing us to bring the potential of microbiome science to even more people, with greater value and easier access than ever before."
Seed's flagship innovation, DS-01® Daily Synbiotic, reflects the company's approach to product development: translating advances in microbiome science through precision formulation, purpose-built delivery technology and rigorous clinical validation. Formulated with 24 scientifically selected probiotic strains and a prebiotic, DS-01® is clinically validated to improve regularity, reduce bloating, and alleviate gas. Its proprietary capsule-in-capsule ViaCap® technology is engineered to protect the probiotic strains through digestion and release them in the colon.
DS-01® has been evaluated in multiple human clinical trials, including the largest randomized, placebo-controlled trial on a probiotic for bloating and gas in healthy adults, published in Nutrients. By the end of the study, 72% of DS-01® participants reported never or rarely feeling bloated.
With an expanding omnichannel presence, Seed is positioned to introduce its next generation of microbiome-targeted products with greater reach and impact. The company plans to expand across both products and retail channels in the years ahead, bringing new gut-directed innovations to a growing mainstream audience.
ˆSource: SPINS, Combined Amazon + Target Sales data, Last 24 weeks ending in January 2026.
About Seed Health
Seed Health is a microbiome science company pioneering clinically validated innovations for gut and whole-body health. Rooted in rigorous research and peer-reviewed studies, Seed is setting new standards for efficacy, safety, and trust in the biotics category. Our flagship innovation, DS-01® Daily Synbiotic, is a pre- and probiotic studied in multiple human clinical trials and trusted by over two million people for its systemic benefits, including gut, skin, immune, and heart health. Our pipeline of gut-directed innovations, developed in collaboration with world-renowned researchers and clinicians, harnesses the microbiome as a driver of longevity, systemic health, and daily well-being. Grounded in the ethos that human and planetary health are interconnected, our environmental research division, SeedLabs, advances microbial interventions to enhance biodiversity and help restore ecosystems impacted by human activity.
Press Contact
press@seed.com
SOURCE Seed Health
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
These Overvalued Stocks Have Plenty of Room to Fall
The 10 Best Companies to Invest in Now
Your Year-End Financial Checklist: 5 Things to Tackle Before 2027
4 Growth Stocks to Buy While They’re Still Undervalued
United States